NasdaqGM - Delayed Quote USD

TransMedics Group, Inc. (TMDX)

Compare
162.89 +1.04 (+0.64%)
At close: August 9 at 4:00 PM EDT
162.05 -0.84 (-0.52%)
After hours: August 9 at 7:21 PM EDT
Loading Chart for TMDX
DELL
  • Previous Close 161.85
  • Open 161.85
  • Bid 162.53 x 600
  • Ask 162.94 x 200
  • Day's Range 160.44 - 166.72
  • 52 Week Range 36.42 - 171.98
  • Volume 717,663
  • Avg. Volume 765,506
  • Market Cap (intraday) 5.427B
  • Beta (5Y Monthly) 1.98
  • PE Ratio (TTM) 5,429.67
  • EPS (TTM) 0.03
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 176.29

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com

584

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMDX

View More

Performance Overview: TMDX

Trailing total returns as of 8/9/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMDX
106.37%
S&P 500
12.04%

1-Year Return

TMDX
145.65%
S&P 500
18.78%

3-Year Return

TMDX
433.19%
S&P 500
20.46%

5-Year Return

TMDX
674.56%
S&P 500
81.89%

Compare To: TMDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMDX

View More

Valuation Measures

Annual
As of 8/9/2024
  • Market Cap

    5.43B

  • Enterprise Value

    5.58B

  • Trailing P/E

    4.07k

  • Forward P/E

    158.73

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    15.35

  • Price/Book (mrq)

    28.58

  • Enterprise Value/Revenue

    15.55

  • Enterprise Value/EBITDA

    184.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.84%

  • Return on Assets (ttm)

    2.45%

  • Return on Equity (ttm)

    1.79%

  • Revenue (ttm)

    358.76M

  • Net Income Avi to Common (ttm)

    3M

  • Diluted EPS (ttm)

    0.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    362.75M

  • Total Debt/Equity (mrq)

    271.99%

  • Levered Free Cash Flow (ttm)

    -240.13M

Research Analysis: TMDX

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

153.00 Low
176.29 Average
162.89 Current
200.00 High
 

Company Insights: TMDX

People Also Watch